The estimated Net Worth of Ronald Nicholas Spaulding is at least $1.48 million dollars as of 23 May 2019. Mr. Spaulding owns over 200 units of Atrion stock worth over $978,710 and over the last 17 years he sold ATRI stock worth over $368,550. In addition, he makes $132,000 as Lead Independent Director at Atrion.
Ronald has made over 2 trades of the Atrion stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 200 units of ATRI stock worth $180,600 on 23 May 2019.
The largest trade he's ever made was selling 500 units of Atrion stock on 26 August 2015 worth over $187,950. On average, Ronald trades about 29 units every 57 days since 2007. As of 23 May 2019 he still owns at least 2,128 units of Atrion stock.
You can see the complete history of Mr. Spaulding stock trades at the bottom of the page.
Ronald Nicholas Spaulding serves as Lead Independent Director of the Company. Mr. Spaulding was the President of Worldwide Commercial Operations of Abbott Vascular and a Vice President and corporate officer of Abbott Laboratories, which he joined in April 2006 upon its acquisition of Guidant Corporation’s vascular intervention assets. Between 2005 and April 2006, Mr. Spaulding served as the President of International Operations of Guidant Corporation, a medical device manufacturer, and also served on the Guidant Management Committee from 2002 until 2005. From 2003 to 2005, he was the President of Europe, Middle East, Africa, and Canada of Guidant Corporation. From 2000 to 2003, Mr. Spaulding served as President of Guidant Corporation’s cardiac surgery business. Mr. Spaulding holds a Master’s degree in Biomedical Engineering and a Bachelor of Science degree in Mechanical Engineering from the University of Miami. Mr. Spaulding’s over 21 years of healthcare experience, including service as an officer of publicly-held companies with medical device operations, his knowledge of regulatory and operational matters affecting the development and marketing of medical devices, and his educational background enable Mr. Spaulding to bring a valuable and unique perspective to our Board.
As the Lead Independent Director of Atrion, the total compensation of Ronald Spaulding at Atrion is $132,000. There are 7 executives at Atrion getting paid more, with David Battat having the highest compensation of $1,626,060.
Ronald Spaulding is 56, he's been the Lead Independent Director of Atrion since 2019. There are 7 older and 2 younger executives at Atrion. The oldest executive at Atrion Corp. is Hugh Morgan, 91, who is the Independent Director.
Ronald's mailing address filed with the SEC is ONE ALLENTOWN PARKWAY, , ALLEN, TX, 75002.
Over the last 21 years, insiders at Atrion have traded over $15,680,153 worth of Atrion stock and bought 1,700 units worth $938,257 . The most active insiders traders include Emile A Battat, David A Battat et Roger F Stebbing. On average, Atrion executives and independent directors trade stock every 79 days with the average trade being worth of $893,625. The most recent stock trade was executed by David A Battat on 1 July 2024, trading 310 units of ATRI stock currently worth $142,575.
atrion corp is a medical device company located in 527 plymouth rd, plymouth, pennsylvania, united states.
Atrion executives and other stock owners filed with the SEC include: